Meeting
2017 ASCO Annual Meeting
Fosaprepitant use in children and adolescents at Memorial Sloan Kettering Cancer Center.
Authors
Dazhi Liu
Memorial Sloan Kettering Cancer Center, New York, NY
Dazhi Liu , Krisoula Horiates , Sherry Mathew , Melissa Pozotrigo , Jennifer Thackray , Michelle Kussin , Shirley Qiong Yan , Brian M. Seyboth , Shakeel Modak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Symptom Management/Supportive Care/Palliative Care
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10575)
DOI
10.1200/JCO.2017.35.15_suppl.10575
Abstract #
10575
Poster Bd #
332
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2014 ASCO Annual Meeting
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153.
First Author: Costantine Albany
Poster
2011 ASCO Annual Meeting
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
First Author: P. J. Hesketh
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan